Akso Health Files Interim Financials, Incorporates into Key Registrations
Ticker: AHG · Form: 6-K · Filed: Jan 3, 2024 · CIK: 1702318
| Field | Detail |
|---|---|
| Company | Akso Health Group (AHG) |
| Form Type | 6-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: interim-financials, 6-K, corporate-filing, registration-statement
TL;DR
**Akso Health just dropped interim financials, now part of their S-8 and F-3 filings.**
AI Summary
Akso Health Group, formerly known as Xiaobai Maimai Inc. and Hexindai Inc., filed a 6-K on January 3, 2024, to provide its six-month interim financial statements for the period ending September 30, 2023. This filing is crucial because it incorporates these financial statements into existing registration statements, specifically Form S-8 (Registration No. 333-223951) and Form F-3s (Registration Nos. 333-250020 and 333-252434), which are used for employee benefit plans and offering securities, respectively. Investors need to review these interim financials to understand the company's recent performance and financial health, as they are now officially part of documents that allow the company to issue shares or offer securities.
Why It Matters
This filing provides updated financial information for Akso Health Group, which is now officially part of documents that allow the company to issue shares or offer securities, directly impacting potential dilution and valuation.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the content of the interim financial statements, which are not detailed here, could reveal significant risks or opportunities.
Analyst Insight
An investor should locate and thoroughly review the actual six-month interim financial statements for the period ending September 30, 2023, to assess Akso Health Group's current financial performance and health, as this filing only announces their availability and incorporation.
Key Numbers
- September 30, 2023 — Interim Financial Statement Period End (The date up to which the financial performance is being reported.)
- January 3, 2024 — Filing Date (The date the 6-K was filed with the SEC.)
- 001-38245 — Commission File Number (Unique identifier for Akso Health Group's SEC filings.)
- 333-223951 — Form S-8 Registration Number (Registration number for employee benefit plans, now incorporating the interim financials.)
- 333-250020 and 333-252434 — Form F-3s Registration Numbers (Registration numbers for offering securities, now incorporating the interim financials.)
Key Players & Entities
- Akso Health Group (company) — registrant filing the 6-K
- Xiaobai Maimai Inc. (company) — former name of Akso Health Group
- Hexindai Inc. (company) — former name of Akso Health Group
- January 2024 (date) — month of the 6-K report
- September 30, 2023 (date) — end of the six-month interim financial statement period
- 001-38245 (number) — Commission File Number for Akso Health Group
- 333-223951 (number) — Registration No. for Form S-8
- 333-250020 (number) — Registration No. for Form F-3s
- 333-252434 (number) — Registration No. for Form F-3s
Forward-Looking Statements
- Akso Health Group's stock price will react to the content of the full interim financial statements once they are publicly available and analyzed. (Akso Health Group) — medium confidence, target: 2024-01-31
- The incorporation of these financials into Form S-8 and F-3s suggests potential future equity offerings or employee stock plan activity. (Akso Health Group) — medium confidence, target: 2024-12-31
FAQ
What is the primary purpose of Akso Health Group's 6-K filing on January 3, 2024?
The primary purpose of Akso Health Group's 6-K filing on January 3, 2024, is to furnish six-month interim financial statements and incorporate these statements into the Company's existing registration statements on Form S-8 (Registration No. 333-223951) and Form F-3s (Registration Nos. 333-250020 and 333-252434).
What period do the interim financial statements cover?
The interim financial statements provided in this 6-K filing cover the six-month period ending September 30, 2023.
Which previous company names did Akso Health Group operate under?
Akso Health Group previously operated under the names Xiaobai Maimai Inc. and Hexindai Inc., with name changes occurring on December 21, 2020, and March 28, 2017, respectively.
Into which specific registration statements are these interim financial statements being incorporated by reference?
These interim financial statements are being incorporated by reference into the Company's registration statements on Form S-8 (Registration No. 333-223951) and on Form F-3s, as amended (Registration Nos. 333-250020 and 333-252434).
What is Akso Health Group's business address as listed in the filing?
Akso Health Group's business address is Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, No. 44, Moscow Road, Qianwan Bonded Port Area, Qingdao Pilot Free Trade Zone, China (Shandong).
Filing Stats: 374 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-01-03 06:18:41
Filing Documents
- ea189757-6k_aksohealth.htm (6-K) — 19KB
- ea189757ex99-1_aksohealth.htm (EX-99.1) — 498KB
- ea189757ex99-2_aksohealth.htm (EX-99.2) — 80KB
- 0001213900-24-000418.txt ( ) — 4946KB
- ahg-20230930.xsd (EX-101.SCH) — 72KB
- ahg-20230930_cal.xml (EX-101.CAL) — 46KB
- ahg-20230930_def.xml (EX-101.DEF) — 254KB
- ahg-20230930_lab.xml (EX-101.LAB) — 499KB
- ahg-20230930_pre.xml (EX-101.PRE) — 271KB
- ea189757-6k_aksohealth_htm.xml (XML) — 592KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibits . Exhibit No. Description 99.1 Unaudited Interim Consolidated Financial Statements as of September 30, 2023 and for the Six Months Ended September 30, 2023 and 2022 99.2 Operating and Financial Review and Prospects in Connection with the Unaudited Interim Consolidated Financial Statements for the Six Months Ended September 30, 2023 and 2022 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 3, 2024 Akso Health Group By: /s/ Yilin Wang Name: Yilin Wang Title: Chief Executive Officer 2